Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib.

Autor: Scott G; Department of Exploratory Clinical Development, Novartis Pharmaceuticals, Horsham, UK. christiane.rordorf@pharma.novartis.com, Vinluan Reynolds C, Milosavljev S, Langholff W, Shenouda M, Rordorf C

Publikováno v: Clinical pharmacokinetics [Clin Pharmacokinet] 2004; Vol. 43 (5), pp. 341-8.